HOOKIPA Pharma Inc. Files 8-K with Corporate Updates
Ticker: HOOK · Form: 8-K · Filed: Jul 10, 2024 · CIK: 1760542
| Field | Detail |
|---|---|
| Company | Hookipa Pharma Inc. (HOOK) |
| Form Type | 8-K |
| Filed Date | Jul 10, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing
TL;DR
HOOKIPA Pharma filed an 8-K on July 9th detailing corporate changes and financial exhibits.
AI Summary
HOOKIPA Pharma Inc. filed an 8-K on July 10, 2024, reporting material modifications to security holder rights and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits, with the earliest event reported being July 9, 2024. The company is incorporated in Delaware and its principal executive offices are located in New York.
Why It Matters
This filing indicates potential changes in HOOKIPA Pharma's corporate structure or security holder rights, which could impact investors and the company's strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative news or significant financial events.
Key Players & Entities
- HOOKIPA Pharma Inc. (company) — Registrant
- July 9, 2024 (date) — Earliest event reported
- July 10, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- New York (location) — Principal Executive Offices
FAQ
What specific material modifications were made to the rights of HOOKIPA Pharma Inc.'s security holders?
The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not elaborated upon in the provided text, requiring further review of the full document.
What are the key amendments to HOOKIPA Pharma Inc.'s articles of incorporation or bylaws?
The filing states there were amendments to the articles of incorporation or bylaws, but the specific nature of these amendments is not detailed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 9, 2024.
Where are HOOKIPA Pharma Inc.'s principal executive offices located?
HOOKIPA Pharma Inc.'s principal executive offices are located at 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, New York, 10118.
What is the SIC code for HOOKIPA Pharma Inc.?
The Standard Industrial Classification (SIC) code for HOOKIPA Pharma Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 799 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2024-07-10 07:00:16
Key Financial Figures
- $0.0001 — e on which registered Common Stock, $0.0001 par value per share HOOK The Nasdaq
Filing Documents
- tm2419049d1_8k.htm (8-K) — 30KB
- tm2419049d1_ex3-1.htm (EX-3.1) — 9KB
- 0001104659-24-078760.txt ( ) — 217KB
- hook-20240709.xsd (EX-101.SCH) — 3KB
- hook-20240709_lab.xml (EX-101.LAB) — 33KB
- hook-20240709_pre.xml (EX-101.PRE) — 22KB
- tm2419049d1_8k_htm.xml (XML) — 4KB
03 Material Modification to Rights of Security Holders
Item 3.03 Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.
03 Amendments to Articles of Incorporation
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On July 9, 2024, HOOKIPA Pharma Inc. (the "Company") filed with the Secretary of State of the State of Delaware a certificate of amendment to its amended and restated certificate of incorporation (the "Charter Amendment") to effect the previously disclosed 1-for-10 reverse stock split of the Company's common stock (the "Reverse Stock Split"). The Reverse Stock Split became effective at 5:00 p.m. Eastern Time on July 9, 2024 (the "Effective Time"). The Charter Amendment provides that, at the Effective Time, every 10 issued and outstanding shares of the Company's common stock were automatically combined into one issued and outstanding share of common stock. The par value per share of the common stock remained unchanged at $0.0001. Fractional shares were not issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive a fractional share received a proportional cash payment. The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder's relative interest in the Company's equity securities, except for any adjustments for fractional shares. As a result of the Reverse Stock Split, proportionate adjustments were made to the conversion ratio for the Company's Class A Common Stock and the conversion prices of the Company's Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series A-2 Convertible Preferred Stock. Proportionate adjustments were also made to the number of shares underlying, and the exercise or conversion prices of, the Company's outstanding stock options and to the number of shares of common stock issuable under the Company's equity incentive plans. The Reverse Stock Split proportionately reduced the number of authorized shares of the Company's common stock from 400,000,000 to 40,000,000. As a result of the Reverse Stock Split and immediately following the Effective Time, t
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 3.1 Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Company. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 10, 2024 HOOKIPA Pharma Inc. By: /s/ Joern Aldag Name: Joern Aldag Title: Chief Executive Officer